​

ACADIA Pharmaceuticals (ACAD) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

ACAD Stock Forecast

ACADIA Pharmaceuticals (ACAD) stock forecast, based on 36 Wall Street analysts, predicts a 12-month average price target of $34.71, with a high of $40.00 and a low of $29.00. This represents a 29.23% increase from the last price of $26.86.

$10 $16 $22 $28 $34 $40 High: $40 Avg: $34.71 Low: $29 Last Closed Price: $26.86

ACAD Stock Rating

ACADIA Pharmaceuticals stock's rating consensus is Buy, based on 36 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 23 Buy (63.89%), 12 Hold (33.33%), 1 Sell (2.78%), and 0 Strong Sell (0.00%).

Buy
Total 36 1 12 23 Strong Sell Sell Hold Buy Strong Buy

ACAD Price Target Upside V Benchmarks

TypeNameUpside
StockACADIA Pharmaceuticals29.23%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts2816
Avg Price Target$37.00$34.25$31.75
Last Closing Price$26.86$26.86$26.86
Upside/Downside37.75%27.51%18.21%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jan, 264961-20
Dec, 254961-20
Nov, 255961-21
Oct, 255861-20
Sep, 255861-20
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jan 06, 2026Ashwani VermaUBS$40.00$26.6650.04%48.92%
Jan 05, 2026Needham$34.00$26.2929.33%26.58%
Dec 16, 2025Piper Sandler$37.00$27.2835.63%37.75%
Dec 15, 2025H.C. Wainwright$37.00$27.0037.04%37.75%
Dec 11, 2025Paul MatteisStifel Nicolaus$25.00$26.81-6.75%-6.92%
Dec 04, 2025Ashwani VermaUBS$35.00$26.2233.49%30.31%
Dec 02, 2025Mizuho Securities$29.00$24.8516.70%7.97%
Sep 25, 2025Deutsche Bank$29.00$21.2136.73%7.97%
Sep 09, 2025UBS$39.00$24.8457.00%45.20%
Aug 08, 2025Ashwani VermaUBS$36.00$24.5146.88%34.03%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jan 06, 2026UBSBuyBuyhold
Jan 06, 2026CitigroupBuyBuyhold
Jan 05, 2026NeedhamBuyBuyhold
Dec 15, 2025H.C. WainwrightBuyBuyhold
Dec 04, 2025UBSBuyBuyhold
Oct 21, 2025CitigroupOutperformBuyinitialise
Sep 11, 2025Cowen & Co.BuyBuyhold
Sep 09, 2025UBSBuyBuyhold
Aug 08, 2025UBSBuyBuyhold
Aug 07, 2025CitigroupOutperformOutperformhold

Financial Forecast

EPS Forecast

$-2 $-1 $0 $1 $2 $3 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-1.05$-1.34$-0.37$1.37----
Avg Forecast$-1.02$-1.32$-0.36$0.72$0.75$1.12$1.67$2.18
High Forecast$-0.94$-1.25$-0.07$1.21$1.19$2.27$2.78$2.32
Low Forecast$-1.08$-1.42$-0.47$0.43$0.24$0.43$0.11$2.07
Surprise %2.94%1.52%2.78%90.28%----

Revenue Forecast

$0 $400M $800M $1B $2B $2B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$484.14M$517.24M$726.44M$957.80M----
Avg Forecast$487.98M$514.79M$719.17M$969.65M$1.05B$1.17B$1.30B$1.44B
High Forecast$509.14M$546.26M$723.91M$975.90M$1.09B$1.18B$1.31B$1.51B
Low Forecast$458.75M$496.61M$709.72M$964.06M$1.02B$1.17B$1.29B$1.39B
Surprise %-0.79%0.47%1.01%-1.22%----

Net Income Forecast

$-350M $-180M $-10M $160M $330M $500M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-167.87M$-215.97M$-61.29M$226.45M----
Avg Forecast$-187.72M$-252.14M$-61.29M$128.51M$134.26M$208.81M$282.56M$357.29M
High Forecast$-150.18M$-201.71M$-49.03M$197.58M$194.99M$371.62M$455.51M$379.72M
Low Forecast$-225.27M$-302.57M$-73.54M$70.93M$38.68M$71.02M$18.15M$339.05M
Surprise %-10.58%-14.34%-76.22%----

ACAD Forecast FAQ

Is ACADIA Pharmaceuticals stock a buy?

ACADIA Pharmaceuticals stock has a consensus rating of Buy, based on 36 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 23 Buy, 12 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that ACADIA Pharmaceuticals is a favorable investment for most analysts.

What is ACADIA Pharmaceuticals's price target?

ACADIA Pharmaceuticals's price target, set by 36 Wall Street analysts, averages $34.71 over the next 12 months. The price target range spans from $29 at the low end to $40 at the high end, suggesting a potential 29.23% change from the previous closing price of $26.86.

How does ACADIA Pharmaceuticals stock forecast compare to its benchmarks?

ACADIA Pharmaceuticals's stock forecast shows a 29.23% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for ACADIA Pharmaceuticals over the past three months?

  • January 2026: 20.00% Strong Buy, 45.00% Buy, 30.00% Hold, 5.00% Sell, 0% Strong Sell.
  • December 2025: 20.00% Strong Buy, 45.00% Buy, 30.00% Hold, 5.00% Sell, 0% Strong Sell.
  • November 2025: 23.81% Strong Buy, 42.86% Buy, 28.57% Hold, 4.76% Sell, 0% Strong Sell.

What is ACADIA Pharmaceuticals’s EPS forecast?

ACADIA Pharmaceuticals's average annual EPS forecast for its fiscal year ending in December 2025 is $0.75, marking a -45.26% decrease from the reported $1.37 in 2024. Estimates for the following years are $1.12 in 2026, $1.67 in 2027, and $2.18 in 2028.

What is ACADIA Pharmaceuticals’s revenue forecast?

ACADIA Pharmaceuticals's average annual revenue forecast for its fiscal year ending in December 2025 is $1.05B, reflecting a 10.06% increase from the reported $957.8M in 2024. The forecast for 2026 is $1.17B, followed by $1.3B for 2027, and $1.44B for 2028.

What is ACADIA Pharmaceuticals’s net income forecast?

ACADIA Pharmaceuticals's net income forecast for the fiscal year ending in December 2025 stands at $134.26M, representing a -40.71% decrease from the reported $226.45M in 2024. Projections indicate $208.81M in 2026, $282.56M in 2027, and $357.29M in 2028.